このエントリーをはてなブックマークに追加
ID 34987
file
creator
Nagao, Saeko
Hattori, Noboru
Kanehara, Masashi
Ishikawa, Nobuhisa
subject
Lung cancer
Bone metastasis
Zoledronic acid
Anti-tumor effect
NDC
Medical sciences
abstract
Bisphosphonates are widely used for the treatment of metastatic skeletal tumors and hypercalcemia resulting from malignant tumors. Zoledronic acid (ZOL), a third-generation bisphosphonate agent, was recently demonstrated to show synergistic antitumor activity of ZOL when combined with chemotherapy in lung cancer patients. However, whether ZOL exerts direct antitumor activity on lung cancer remains unclear. Here, we report an atypical case encountered while treating a 57-year-old woman with pulmonary adenocarcinoma and multiple metastases of the liver, left adrenal gland, and bone. The nonskeletal lesions, consisting of the primary lesion and hepatic metastasis, regressed after treatment with ZOL alone. We believe this case demonstrates a possible antitumor effect of ZOL against lung cancer.
journal title
Hiroshima Journal of Medical Sciences
volume
Volume 60
issue
Issue 1
start page
7
end page
9
date of issued
2011-03
publisher
Hiroshima University Medical Press
issn
0018-2052
ncid
language
eng
nii type
Departmental Bulletin Paper
HU type
Departmental Bulletin Papers
DCMI type
text
format
application/pdf
text version
publisher
rights
(c) Hiroshima University Medical Press.
department
Graduate School of Biomedical Science
他の一覧



Last 12 months's access : ? times
Last 12 months's DL: ? times


This month's access: ? times
This month's DL: ? times